AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)

Grant

Date/time Interval

  • November 7, 2017 - November 6, 2022
  • Total Award Amount

  • 9000.00
  • Direct Costs

  • 6923.00
  • Sponsor Award Id

  • Contributor

  • Galtarossa Xavier, Ana   Investigator  
  • Kutny M.D., Matthew   Principal Investigator  
  • Wolfson-Stockman M.D., Julie   Investigator